Immunostimulatory agents such as Toll-like receptor (TLR) agonists have shown promising antitumor efficacy but are associated with therapy-related toxicities when delivered systemically. Immune-stimulating antibody conjugates are now shown to deliver TLR agonists with potent preclinical antitumor activities.
References
Mullins, S. R. et al. J. Immunother. Cancer 7, 244 (2019).
Ackerman, S.E. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-00136-x (2020).
Demaria, O. et al. Nature 574, 45–56 (2019).
McWhirter, S. M. & Jefferies, C. A. Immunity 53, 78–97 (2020).
Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Ann. Oncol. 28, xii33–xii43 (2017).
Engel, A. L., Holt, G. E. & Lu, H. Expert Rev. Clin. Pharmacol. 4, 275–289 (2011).
Li, J. et al. J. Immunol. 179, 2493–2500 (2007).
Singh, M. et al. J. Immunol. 193, 4722–4731 (2014).
Zhou, Z., Yu, X., Zhang, J., Tian, Z. & Zhang, C. Cancer Lett. 369, 298–306 (2015).
Gadd, A. J. R., Greco, F., Cobb, A. J. A. & Edwards, A. D. Bioconjug. Chem. 26, 1743–1752 (2015).
Caswell, D. R. & Swanton, C. BMC Med. 15, 133 (2017).
Ribas, A. et al. Cancer Discov. 8, 1250–1257 (2018).
Junker, F., Gordon, J. & Qureshi, O. Front. Immunol. 11, 1393 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
O.D. and E.V. are employees of Innate Pharma.
Rights and permissions
About this article
Cite this article
Demaria, O., Vivier, E. ISACs take a Toll on tumors. Nat Cancer 2, 12–13 (2021). https://doi.org/10.1038/s43018-020-00152-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-00152-x
- Springer Nature America, Inc.